Protocol Ledger

NCT07284602 · Phase III · RECRUITING

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase III clinical trial protocol NCT07284602 sponsored by PureTech in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-26 Enrollment: 1,100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284602
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284602
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284602
Consolidated Lead SponsorPureTech
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,100 participants (ESTIMATED)
Registered Start Date2026-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07284602
Hospital Research SiteLocationSite Profile
Renown Regional Medical CenterReno, NVOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI